Gain Therapeutics Reports Positive Interim Phase 1b Data for Parkinson's Drug GT-02287, Showing Sustained Benefits
GANX sits 35% above its 52-week low of $1.41.
Summary
Gain Therapeutics announced positive interim 150-day data from its Phase 1b study of GT-02287 for Parkinson's disease, demonstrating sustained biomarker reductions and clinical stability.
Key Events · Product Development and Regulatory · GANX
-
Positive Interim Phase 1b Data
Interim 150-day data from the GT-02287 Phase 1b study for Parkinson's disease showed sustained positive results, supporting continued development.
-
Significant Biomarker Reduction
Participants with elevated baseline glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF) showed an average 81% decrease after 90 days, with DOPA decarboxylase (DDC) also decreasing.
-
Stable Clinical Scores
MDS-UPDRS scores remained stable and durable across the overall study population after 150 days, with greater benefit observed in patients with high baseline GluSph.
-
Strong Tolerability
16 of 19 participants who completed Part 1 of the study chose to continue in the nine-month extension (Part 2), further supporting the drug's tolerability.
Analysis · GANX · Life Sciences
This positive clinical update is critical for Gain Therapeutics, especially given its recent 'going concern' warning. Sustained positive data from the Phase 1b study, including significant biomarker improvements and stable clinical scores for GT-02287 in Parkinson's disease, provides crucial validation for its lead asset. This progress is essential for the company's ability to secure future financing and advance the drug to a planned Phase 2 trial.
At the time of this filing, GANX was trading at $1.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.9M. The 52-week trading range was $1.41 to $4.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.